IRIS
BENNETT, DAVID
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 8.170
NA - Nord America 7.817
AS - Asia 3.627
SA - Sud America 606
AF - Africa 185
OC - Oceania 16
Continente sconosciuto - Info sul continente non disponibili 5
Totale 20.426
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.665
IT - Italia 2.150
RU - Federazione Russa 1.789
GB - Regno Unito 1.327
SG - Singapore 1.105
CN - Cina 1.014
IE - Irlanda 906
BR - Brasile 507
VN - Vietnam 495
DE - Germania 446
SE - Svezia 364
FR - Francia 363
HK - Hong Kong 338
UA - Ucraina 234
FI - Finlandia 222
IN - India 150
KR - Corea 115
ZA - Sudafrica 96
CA - Canada 92
ES - Italia 75
TR - Turchia 59
BD - Bangladesh 58
NL - Olanda 53
PL - Polonia 53
CZ - Repubblica Ceca 46
JP - Giappone 46
IQ - Iraq 42
AR - Argentina 38
MX - Messico 37
AT - Austria 25
CI - Costa d'Avorio 24
BE - Belgio 23
ID - Indonesia 22
UZ - Uzbekistan 22
MA - Marocco 17
IR - Iran 16
NG - Nigeria 16
AU - Australia 15
VE - Venezuela 15
AZ - Azerbaigian 14
EC - Ecuador 14
PH - Filippine 14
AE - Emirati Arabi Uniti 13
CH - Svizzera 13
JO - Giordania 12
PK - Pakistan 12
SA - Arabia Saudita 12
LT - Lituania 11
IL - Israele 10
KE - Kenya 10
EG - Egitto 9
KZ - Kazakistan 9
MY - Malesia 9
GR - Grecia 8
PE - Perù 8
HU - Ungheria 7
MK - Macedonia 7
RO - Romania 7
JM - Giamaica 6
PT - Portogallo 6
UY - Uruguay 6
BO - Bolivia 5
CO - Colombia 5
CY - Cipro 5
DK - Danimarca 5
KG - Kirghizistan 5
PY - Paraguay 5
BG - Bulgaria 4
BY - Bielorussia 4
CR - Costa Rica 4
DZ - Algeria 4
NO - Norvegia 4
CL - Cile 3
EU - Europa 3
GE - Georgia 3
HR - Croazia 3
LK - Sri Lanka 3
PA - Panama 3
AL - Albania 2
AM - Armenia 2
ET - Etiopia 2
GD - Grenada 2
HN - Honduras 2
LB - Libano 2
LV - Lettonia 2
MD - Moldavia 2
NP - Nepal 2
OM - Oman 2
PS - Palestinian Territory 2
QA - Qatar 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
SY - Repubblica araba siriana 2
TJ - Tagikistan 2
TN - Tunisia 2
XK - ???statistics.table.value.countryCode.XK??? 2
AF - Afghanistan, Repubblica islamica di 1
AO - Angola 1
BB - Barbados 1
BH - Bahrain 1
Totale 20.405
Salva come PNG Salva come JPEG
Città #
Dallas 1.402
Southend 1.108
Dublin 890
Singapore 708
Fairfield 578
Ashburn 577
Moscow 526
Chandler 443
Santa Clara 393
San Jose 359
Hong Kong 311
Beijing 285
Siena 284
Woodbridge 254
Seattle 215
Wilmington 208
Ann Arbor 200
Milan 192
Cambridge 183
Jacksonville 180
Houston 179
Hefei 176
Los Angeles 173
Munich 165
New York 156
Ho Chi Minh City 147
Florence 130
Helsinki 123
Princeton 120
Seoul 113
Council Bluffs 109
Lauterbourg 105
Hanoi 95
Johannesburg 87
The Dalles 86
Rome 62
Boardman 58
Dearborn 54
Buffalo 53
Chicago 53
Nanjing 53
Dong Ket 50
London 49
Turku 47
Orem 45
Shanghai 44
Warsaw 44
Frankfurt am Main 43
Tokyo 43
Fremont 42
Málaga 42
São Paulo 40
San Mateo 37
Nuremberg 36
Catania 35
Chennai 35
Bengaluru 28
Montreal 27
Da Nang 26
Menlo Park 26
San Diego 26
Toronto 25
Abidjan 24
Atlanta 24
Izmir 24
Brno 23
Düsseldorf 23
Denver 22
Brussels 21
Manchester 21
Columbus 20
Lappeenranta 20
Mumbai 20
Nanchang 20
Washington 20
Olomouc 19
Poplar 19
Redondo Beach 19
Tashkent 19
Baghdad 18
Brooklyn 18
Guangzhou 18
Lastra a Signa 18
San Francisco 18
Shenyang 18
Gavirate 17
Paris 17
Phoenix 17
Abuja 16
Changsha 16
Padova 16
Haiphong 15
Amsterdam 14
Boston 14
Hebei 14
Messina 14
Bologna 13
Brescia 13
Dhaka 13
Mexico City 13
Totale 13.071
Salva come PNG Salva come JPEG
Nome #
La chitotriosidasi: un sensibile biomarker di sarcoidosi 1.039
A first update on mapping the human genetic architecture of COVID-19 575
Towards a functional proteomics approach to the comprehension of idiopathic pulmonary fibrosis, sarcoidosis, systemic sclerosis and pulmonary Langerhans cell histiocytosis 388
The polymorphism L412F in TLR3 inhibits autophagy and is a marker of severe COVID-19 in males 387
An explainable model of host genetic interactions linked to COVID-19 severity 366
Antirheumatic agents in covid-19: is IL-6 the right target? 355
Chitotriosidase: a biomarker of activity and severity in patients with sarcoidosis 349
Peripheral biomarkers' panel for severe COVID-19 patients 316
Bronchoalveolar lavage proteomic analysis in pulmonary fibrosis associated with systemic sclerosis: S100A6 and 14-3-3ε as potential biomarkers 305
Rare variants in Toll-like receptor 7 results in functional impairment and downregulation of cytokine-mediated signaling in COVID-19 patients 293
Shorter androgen receptor polyQ alleles protect against life-threatening COVID-19 disease in European males 283
Carriers of ADAMTS13 Rare Variants Are at High Risk of Life-Threatening COVID-19 273
Exhaled nitric oxide in interstitial lung diseases 271
Elevated level of Galectin-1 in bronchoalveolar lavage of patients with idiopathic pulmonary fibrosis 269
Airway-Centered Pleuroparenchymal Fibroelastosis Associated with Non-Necrotizing Granulomas: A Rare New Entity 262
Idiopathic pulmonary fibrosis a rare disease with severe bone fragility 261
Serial KL-6 analysis in patients with idiopathic pulmonary fibrosis treated with nintedanib 261
Familial pulmonary fibrosis: Clinical and radiological characteristics and progression analysis in different high resolution-CT patterns 256
C9orf72 intermediate repeats confer genetic risk for severe covid-19 pneumonia independently of age 253
Diagnosis of idiopathic pulmonary fibrosis by virtual means using “IPFdatabase”- a new software 252
Prognostic bioindicators in severe COVID-19 patients 247
Serial KL-6 measurements in COVID-19 patients 246
Mortality on the Waiting List for Lung Transplantation in Patients with Idiopathic Pulmonary Fibrosis: A Single-Centre Experience 245
Posttransplant solid organ malignancies in lung transplant recipients: A single-center experience and review of the literature 243
Gain- and Loss-of-Function CFTR Alleles Are Associated with COVID-19 Clinical Outcomes 242
Serum chitotriosidase levels in patients with allergic and non-allergic asthma 238
Serum amyloid A in patients with idiopathic pulmonary fibrosis 236
Bronchial stenosis following lung transplant: An innovative approach with a modified endobronchial emphysema valve 235
Rituximab Therapy in Interstitial Lung Disease associated with Rheumatoid Arthritis 235
Diffuse panbronchiolitis in a patient with common variable immunodeficiency: a casual association or a pathogenetic correlation? 232
COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs 226
Pirfenidone therapy for familial pulmonary fibrosis: a real-life study. 224
Acute exacerbation of idiopathic pulmonary fibrosis after inhalation of a water repellent 223
Serum KL-6 concentrations as a novel biomarker of severe COVID-19 219
Strategies for Maximising Lung Utilisation in Donors After Brain and Cardiac Death: A Narrative Review 214
Pirfenidone in chronic lung allograft dysfunction: a single cohort study 214
SARS-CoV-2 in pleural fluid in a kidney transplant patient 214
Ultra-rare RTEL1 gene variants associate with acute severity of COVID-19 and evolution to pulmonary fibrosis as a specific long COVID disorder 213
Pirfenidone in idiopathic pulmonary fibrosis: real-life experience in the referral centre of Siena 213
Incidence and risk factors for respiratory tract bacterial colonization and infection in lung transplant recipients 209
Coronavirus HKU 1 infection with bronchiolitis, pericardial effusion and acute respiratory failure in obese adult female 208
WES profiling of COVID-19 204
Extracorporeal Photopheresis in Lung Transplantation 200
Whole-genome sequencing reveals host factors underlying critical COVID-19 199
Controversial role of RAGE in the pathogenesis of idiopathic pulmonary fibrosis 199
Chitotriosidase: a sensitive biomarker of sarcoidosis 199
Oxidative stress in the pathogenesis of diffuse lung diseases: a review 197
Proteomic investigation of pulmonary sarcoidosis 197
Impact of SARS-CoV-2 outbreak on heart and lung transplant: a patient-perspective survey 196
Collagen Type IV Alpha 5 Chain in Bronchiolitis Obliterans Syndrome After Lung Transplant: The First Evidence 195
Alteration of Immune-checkpoint after specific stimulation with CMV antigens in pre-LTx patients 195
Human Chitotriosidase: a sensitive biomarker of sarcoidosis 193
Biomarkers in sarcoidosis: The contribution of system biology 193
Regulatory and Effector Cell Disequilibrium in Patients with Acute Cellular Rejection and Chronic Lung Allograft Dysfunction after Lung Transplantation: Comparison of Peripheral and Alveolar Distribution 191
BIOMARKERS WITH CLINICAL SIGNIFICANCE IN PATIENTS WITH INTERSTITIAL LUNG DISEASES 190
IPF mortality in waiting list for lung transplantation 188
Anti-Cytosolic 5′-Nucleotidase 1A in the Diagnosis of Patients with Suspected Idiopathic Inflammatory Myopathies: An Italian Real-Life, Single-Centre Retrospective Study 179
Helicobacter pylori antibody positivity in idiopathic pulmonary fibrosis 175
Peripheral lymphocyte subset monitoring in COVID-19 Italian patients 174
Mortalità in lista per trapianto di polmone in pazienti affetti da fibrosi polmonare idiopatica 174
Timing of Osteoporotic Vertebral Fractures in Lung and Heart Transplantation: A Longitudinal Study 168
null 165
Rischio infettivo nel trapianto di polmone per fibrosi polmonare: analisi retrospettiva 165
Familial pulmonary fibrosis: Clinical-functional and radiological features 164
Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international case-cohort study 164
New concepts in the pathogenesis of sarcoidosis 162
Characterization of NKG2-A/-C, Kir and CD57 on NK Cells Stimulated with pp65 and IE-1 Antigens in Patients Awaiting Lung Transplant 162
Helicobacter pylori seroprevalence in patients with idiopathic pulmonary fibrosis 158
Comparative proteomic analysis of bronchoalveolar lavage of familial and sporadic cases of idiopathic pulmonary fibrosis 156
Outcome of ECMO bridge to lung transplantation: a single cohort study 152
IPFdatabase - A new tool for a correct application of idiopathic pulmonaty fibrosis guidelines 151
Incidenza e fattori di rischio per colonizzazione ed infezione respiratoria batterica a 30 giorni in pazienti trapiantati di polmone 150
Markers of Bronchiolitis Obliterans Syndrome after Lung Transplant: Between Old Knowledge and Future Perspective 148
Longitudinal immunogenicity cohort study of SARS-CoV-2 mRNA vaccines across individuals with different immunocompromising conditions: heterogeneity in the immune response and crucial role of Omicron-adapted booster doses 147
Cavernous sinus syndrome due to neurosarcoidosis in adolescence: a diagnosis not to be missed 147
The Role of Galectins in Chronic Lung Allograft Dysfunction 147
Rituximab-induced hypogammaglobulinaemia in patients affected by idiopathic inflammatory myopathies: a multicentre study 146
null 145
Cytomegalovirus Infection Is Associated with Development of Chronic Lung Allograft Dysfunction 144
Immune checkpoint analysis of T-cell responses to pp65 and IE-1 antigens in end-stage lung diseases 141
Valutazione dell'ossido nitrico nell'esalato delle polmoniti interstiziali idiopatiche 138
Exhaled nitric oxide and carbon monoxide in lung transplanted patients 134
Pulse oximetry oxyhemoglobin saturation in patients with idiopathic pulmonary fibrosis 131
Relapses of idiopathic inflammatory myopathies after vaccination against COVID19: a real-life Italian study 127
null 121
Lung transplantation in patients with previous or unknown oncological disease: evaluation of short- and long-term outcomes 120
Donor-Recipient Mismatch in Lung Transplantation: The Role of Graft Sizing in Clinical Outcomes 119
Calgranulin B and KL-6 in Bronchoalveolar Lavage of Patients with IPF and NSIP 111
NK and T cell in patients with end-stage lung disorders waiting for lung transplantation in response to CMV infection 106
null 106
NK and T cells responses to CMV in patients awaiting for lung transplantation 105
Common Molecular Pathways Between Post-COVID19 Syndrome and Lung Fibrosis: A Scoping Review 104
Objective Effects and Patient Preferences for Ambulatory Oxygen in Fibrotic Interstitial Lung Disease With Isolated Exertional Hypoxaemia: A Placebo‐Controlled 6‐Minute Walk Test Study 103
Nintedanib in Idiopathic Pulmonary Fibrosis: a single-centre real-life experience 103
Human chitotriosidase analysis: a reliable biomarker of sarcoidosis severity 102
Assessing Short- and Medium-Term Outcomes of Lung Transplantation in Elderly Recipients: A Comparative Age-Based Analysis 99
Calgranulin B/S100A9 and KL-6 in bronchoalveolar lavage of patients with IPF and NSIP 97
Erratum: Chitotriosidase: a biomarker of activity and severity in patients with sarcoidosis (Respiratory Research (2020) 21 (6) DOI: 10.1186/s12931-019-1263-z) 80
A novel web-based tool for lung transplant patients undergoing extracorporeal photopheresis 71
Valutazione prognostica della Siero Amiloide A in pazienti affetti da Fibrosi Polmonare Idiopatica. 47
Totale 20.634
Salva come PNG Salva come JPEG
Categoria #
all - tutte 62.994
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 62.994
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021255 0 0 0 0 0 0 0 0 0 0 132 123
2021/20221.230 93 153 86 97 71 47 57 72 50 118 146 240
2022/20231.799 145 187 195 225 152 266 157 151 154 74 57 36
2023/20241.752 76 49 179 89 80 408 532 67 15 48 51 158
2024/20253.150 108 161 417 152 371 198 169 164 199 139 355 717
2025/20267.815 553 993 1.186 1.053 1.687 304 1.007 243 269 507 13 0
Totale 20.784